Published On: Wed, Oct 19th, 2016

Heat Biologics, Inc. (HTBX) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of Heat Biologics, Inc. (HTBX).

Most recent broker ratings

09/14/2016 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 2.75 price target on the stock.

08/17/2016 – Noble Financial began new coverage on Heat Biologics, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.

02/04/2016 – Heat Biologics, Inc. was downgraded to “speculative buy” by analysts at Cantor Fitzgerald.

09/03/2015 – Heat Biologics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock.

05/18/2015 – Heat Biologics, Inc. was upgraded to “hold” by analysts at Zacks.

The share price of Heat Biologics, Inc. (HTBX) was down -0.85% during the last day of trading, with a day high of 1.22. 283586 shares were traded during the last session.

The stock’s 50 day moving average is 1.34 and its 200 day moving average is 0.95. The stock’s market capitalization is 22.80M. Heat Biologics, Inc. has a 52-week low of 0.40 and a 52-week high of 4.98.

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.